Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929619 | 0.92 | DNM1 (0.40) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL19929624 | 0.79 | MEN1 (0.41) | DNM1KMT2ABBOX1LMNA | |
| SCHEMBL19929621 | 0.71 | MEN1 (0.38) | DNM1KMT2ABBOX1LMNA | |
| Hydrochloric Acid SCHEMBL31017695 | 0.70 | LMNA (0.66) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL15112915 | 0.70 | LMNA (0.46) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL14754154 | 0.69 | DNM1 (0.77) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL9935426 | 0.69 | DNM1 (0.67) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| Hydrochloric Acid SCHEMBL31233472 | 0.68 | LMNA (0.44) | DNM1HTTKMT2AHSP90AA1RAD52 | |
| SCHEMBL38103898 | 0.67 | TSHR (0.42) | KMT2ALMNA | |
| SCHEMBL13664374 | 0.67 | DNM1 (0.82) | DNM1HTTKMT2AHSP90AA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064738-A1 | METHOD OF TREATING INFECTIONS USING SILOXANE DERIVATIVES | KIMMERLING HOLDINGS GROUP, LLC | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064738-A1 | METHOD OF TREATING INFECTIONS USING SILOXANE DERIVATIVES | LSS, ITGAV, RPL35 | DNM1 3705/4885HTT 4593/4885KMT2A 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.